Status:
COMPLETED
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will explore the correlation of biomarkers with response rate, and the overall efficacy and safety, of Avastin in combination with carboplatin-based chemotherapy in patients with advanced o...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- locally advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC);
- \>=1 measurable tumor lesion;
- ECOG performance status 0-1.
Exclusion
- prior chemotherapy or treatment with another systemic anti-cancer agent;
- evidence of CNS metastases;
- history of grade 2 or higher hemoptysis;
- evidence of tumor invading or abutting major blood vessels;
- malignancies other than NSCLC within 5 years prior to randomization, other than adequately treated cancer in situ of cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS;
- clinically significant cardiovascular disease;
- current or recent use of aspirin (\>325mg/day) or full dose anticoagulants or thrombolytic agents for therapeutic purposes.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
303 Patients enrolled
Trial Details
Trial ID
NCT00700180
Start Date
September 1 2008
End Date
September 1 2012
Last Update
September 25 2014
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
St Leonards, New South Wales, Australia, 2065
2
Adelaide, South Australia, Australia, 5041
3
Adelaide, South Australia, Australia, 5065
4
Box Hill, Victoria, Australia, 3128